ameera patel

TidalSense has developed a handheld CO2-sensor device with machine learning interpretation that diagnoses COPD in under 4 minutes versus 1 hour for legacy spirometry, has achieved Class 2A regulatory clearance and early NHS deployment with overwhelming demand, and is pursuing FDA clearance to access the US market and China's 100 million COPD patients.

TidalSense has developed a handheld CO2-sensor device with machine learning interpretation that diagnoses COPD in under 4 minutes versus 1 hour for legacy spirometry, with NHS deployment showing overwhelming demand and plans for FDA clearance and China market entry.

Crossborder Impact Ventures led TidalSense's $19M round, sharing the company's ambition to scale globally and address the diagnostic gap in low- and middle-income countries where COPD testing access is near zero.

CEO Ameera Patel describes a handheld COPD diagnostic device using CO2 sensing and ML interpretation that delivers results in under 4 minutes vs 1 hour for spirometry, with regulatory clearance, NHS deployment, and inbound demand from 60+ countries.